Skip to main content

Tweets

UK longitudinal study 46 adult PsA pts w/ BMI ≥25 showed use of digital wt. & Dz app (vs no app) improved weight loss (− 1.55 vs − 0.18 kg), dz activity by CPDAI (p < 0.001), esp w/ arthritis (p 0.017) & enthesitis (p  0.034) domains. Weight loss correlated w/ dz activity https://t.co/Y9zVyPmsNl
Dr. John Cush @RheumNow ( View Tweet )
7 minutes 17 seconds ago
🚨NOW IN THE POSTER HALL: Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years Check out the data in RA, PsA, AS, and nr-axSpA presented at EULAR 2026: https://t.co/SFqBCUIxio Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/LWsGQKPko8
Dr. John Cush @RheumNow ( View Tweet )
9 minutes 28 seconds ago
More than the Meds: Obesity Care in Rheumatology In the final webinar in this series, we move beyond the medication to explore what comprehensive obesity care can look like in rheumatology practice. Experts discuss practical approaches to patient conversations, lifestyle https://t.co/MPehqX7jJJ
Dr. John Cush @RheumNow ( View Tweet )
1 hour 38 minutes ago
Remission – Believe it or Not (10.2.2026) Dr, Jack Cush reviews the news and journal articles from the past week on RheumNow. https://t.co/a4N5MnSJSl https://t.co/xdKi7nWFX7
Dr. John Cush @RheumNow ( View Tweet )
15 hours 39 minutes ago
T-cell engager blinatumomab (CD3xCD19 TCE) was used for Deep B-cell depletion in 15 resistant RA pts (MDR-RA). @wk 12 9/15 CDAI LDA, 3/15 CDAI remission. Synovial B cells were depleted (4 of 5 biopsies) but not in lymph nodes. Later, 14/15 flared. No ICANs, 3/15 w/ CRS (gr 1) https://t.co/ddLb7lIHka
Dr. John Cush @RheumNow ( View Tweet )
17 hours 9 minutes ago
Metanalysis of IVIG in scleroderma (11 studies, 363 pts) showed IVIG to be safe; signif improvement in skin by mRSS (SMD −0.59; p 0.0019) & GI Dz (SMD −0.73; p 0.0012; I2 = 0%). W/ inflam myopathy signif reduction in CK (SMD −0.53; p<0.001) https://t.co/h53FrACCgA https://t.co/qavoD3Vren
Dr. John Cush @RheumNow ( View Tweet )
19 hours 24 minutes ago
Biogen announced the 52 week OL results of AMETHYST Phase 2/3 RCT of litifilimab in 93 #CLE pts. Betw wk 24 & 52, pts improved w/ clear skin (27.2%; CLA IGA 0-1) & 29% CLASI-70 (dz activity) https://t.co/61zxVhUwuj https://t.co/9oGXGcom2m
Dr. John Cush @RheumNow ( View Tweet )
20 hours 38 minutes ago
2 cohorts of GC naive, suspected (n 185) PMR pts studied with MSK ultrasound - 67% Dx w/ PMR clinically. No single MSK US finding was ound pathognomonic for PMR. Best specificity (85-93%) was 1+ inflammatory lesion in both the shoulder & hip girdles https://t.co/XOXGeTBl5m https://t.co/3GADGo73l1
Dr. John Cush @RheumNow ( View Tweet )
22 hours 37 minutes ago
Using national survey data of adults (62-85 yrs) saw no change in Rx Med (84% vs 85%) or dietary supplement (66% vs 67%) use betw 2015-2016 & 2021-2013. But OTC declined (60% vs 55%; P = .04). Polypharmacy signif incr. Drug-drug interactions declined (26% vs 22%; P .02) w/ https://t.co/16xPyKS2aU
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Ambient AI in Rheumatology Practice: Less Typing or Less Human? Rheumatology has become a sedentary, computer-based job. We sit at our computers to pre-chart, type during patient visits, and bring notes home to finish on laptops while sitting on the couch. Do you spend more https://t.co/zr56f7iCrJ
Dr. John Cush @RheumNow ( View Tweet )
1 day 14 hours ago
Danish national study (2003-2024) of 51,401 #PMR pts (24K PCPs, 27K secondary MDs): PMR incidence = 112/100K. PMR decr 53% in primary care & incr 30% in secondary care (overall 12% decline). Among PMR, GCA rate was 5.4/1,000 PYs, w/ median 68 days from PMR Dx. 28% & 22% were https://t.co/1VlI5r1r0L
Dr. John Cush @RheumNow ( View Tweet )
1 day 16 hours ago
Multicenter retrosp study 2865 #RA pts (dz duration 2 yrs) starting b/tsDMARDs (TNFi, IL-6i, RTX, ABA, JAKi) - 50% were on steroids (GC). At 3 & 6 mos, only 26% & 37% D/C GC. GC D/C more w/ JAKi (24 v 17%). Predictors on NON-D/C: Chronic GC, HTN, TNFi, RTX, ABA (vs JAKi) https://t.co/JSve6M9hwm
Dr. John Cush @RheumNow ( View Tweet )
1 day 18 hours ago
Petri SLE Pearls: An Update At the CCR West 2026 conference in Huntington Beach, California, Dr. Michelle Petri updated her Petri Pearls. Some are derived from new data, while others are from her extensive experience caring for patients with systemic lupus erythematosus (SLE). https://t.co/SftiqcqbLa
Dr. John Cush @RheumNow ( View Tweet )
1 day 19 hours ago
Italian retrospective study of 36 difficult #GCA pts (89% relapsed; 72% prev TCZ) showed Clinical remission 85%, 81%, & 83% at 3, 6, & 12 mos. GC-free remission increased to 15%, 28%, & 40% at 3, 6, & 12 mos. GCs d/c in 43%. Results at odds w/ ph III GCAptAIN RCT where SEC https://t.co/ufCeaJnVXk
Dr. John Cush @RheumNow ( View Tweet )
1 day 21 hours ago
Serum Abs against IL-1 recept antagonist (aIL-1Ra) were studied in 46 adult-onset Still’s Dz (AOSD not on anakinra) pts & found signif. higher in AOSD vs controls (p=0.003); but levels did not differ between active vs inactive AOSD https://t.co/w6KvLyv1j8 https://t.co/IuQ1SHLDF8
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
×